Headlines about K2M Group (NASDAQ:KTWO) have trended positive on Monday, Accern Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. K2M Group earned a media sentiment score of 0.37 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 47.2549492726394 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
K2M Group (NASDAQ:KTWO) opened at $20.85 on Monday. The firm has a market cap of $903.41, a PE ratio of -21.49 and a beta of 1.35. K2M Group has a 12 month low of $16.44 and a 12 month high of $25.99. The company has a quick ratio of 1.67, a current ratio of 3.06 and a debt-to-equity ratio of 0.29.
K2M Group (NASDAQ:KTWO) last issued its quarterly earnings results on Wednesday, November 1st. The medical device company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.01). The company had revenue of $62.65 million during the quarter, compared to analysts’ expectations of $62.69 million. K2M Group had a negative net margin of 16.22% and a negative return on equity of 16.02%. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.19) earnings per share. equities analysts anticipate that K2M Group will post -0.85 earnings per share for the current fiscal year.
Several research firms have recently issued reports on KTWO. Needham & Company LLC lowered their target price on shares of K2M Group from $27.00 to $26.00 and set a “strong-buy” rating on the stock in a research note on Thursday, November 2nd. ValuEngine lowered shares of K2M Group from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. BidaskClub lowered shares of K2M Group from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Oppenheimer reissued a “buy” rating and set a $24.00 target price on shares of K2M Group in a research note on Friday, November 10th. Finally, Barclays reissued a “buy” rating and set a $25.00 target price on shares of K2M Group in a research note on Tuesday, January 9th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $24.50.
WARNING: “K2M Group (KTWO) Receiving Favorable Press Coverage, Report Finds” was first published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.truebluetribune.com/2018/01/22/k2m-group-ktwo-receiving-favorable-press-coverage-report-finds.html.
About K2M Group
K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.
Receive News & Ratings for K2M Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group and related companies with MarketBeat.com's FREE daily email newsletter.